CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (ticker: TENK) is the public entity formed through the business combination of TenX Keane Acquisition Corp. and Citius Oncology, Inc., a commercial-stage oncology spinout of Citius Pharmaceuticals. TenX Keane Acquisition Corp., sponsored by TenX Capital, completed its SPAC initial public offering in 2021 with a stated focus on the healthcare and life sciences sector. The company submitted an 8-K current report to the SEC on June 18, 2024, under accession number 0001493152-24-024236, reflecting ongoing corporate activity in the post-merger period. Citius Oncology's portfolio centers on oncology therapeutics, including an FDA-approved asset targeting cutaneous T-cell lymphoma. Sign up at SpacDesk for full filing histories, deal timelines, and analytics on TENK and the broader SPAC market.